CB2 Receptor Activation Reduced HIV Replication in Brain Immune Cells | Research

The takeaway

The synthetic CB2 agonist JWH-133 reduced HIV replication in both macrophages and microglia, with cell-type-specific anti-inflammatory effects and distinct molecular pathways.

HIV/neuroimmunology researchers, cannabinoid pharmacologists, HAND treatment researchers

What the researchers found

CB2 activation with JWH-133 reduced HIV replication in primary macrophages and iPSC-derived microglia at different doses corresponding to each cell type's basal endocannabinoid expression. JWH-133 broadly reduced cytokine release from HIV-infected macrophages but not microglia. In microglia, CB2 activation reduced NLRP3 inflammasome activation without affecting NF-kB signaling. RNA-seq revealed distinct pathway effects: interferon/stress response in macrophages vs. homeostatic pathways in microglia.

Why it matters

Brain-resident immune cells serve as HIV reservoirs in the central nervous system and drive neuroinflammation. CB2 agonists could potentially address both viral persistence and neuroinflammation, two major challenges in HIV-associated neurocognitive disorders.

The numbers in context

JWH-133 reduced HIV replication in macrophages and microglia at cell-type-specific doses. Broad cytokine reduction in macrophages. NLRP3 inflammasome activation reduced in microglia. Distinct RNA-seq pathway signatures per cell type.

How the study worked

In vitro study using primary human monocyte-derived macrophages and iPSC-derived microglia infected with HIV and treated with the CB2-specific agonist JWH-133. Assessed HIV replication, cytokine release, RNA-seq transcriptomics, and inflammasome activation.

What this study cannot tell us

In vitro study using isolated cell types, not the complex brain environment. iPSC-derived microglia may not fully recapitulate primary microglia. Single CB2 agonist tested. No in vivo validation. HIV strain specificity not assessed.

How to read the evidence

Rigorous in vitro characterization with transcriptomics, but lack of in vivo validation keeps this at preliminary.

When this study was published

Recently published laboratory research.

The bigger picture

The cell-type specificity of CB2 agonist effects is important for drug development: a single CB2-targeted therapy may work differently in different brain cell types, which could have both beneficial and unexpected consequences.

Questions still open

Would CB2 agonists reduce the HIV brain reservoir in animal models?
Could CB2-targeted therapy complement antiretroviral treatment for HAND?

Common questions

Could cannabis help with HIV in the brain?

This lab study found that activating CB2 receptors reduced HIV replication in brain immune cells. However, this used a specific synthetic compound, not cannabis, and has not been tested in living organisms.

What are CB2 receptors?

CB2 receptors are part of the endocannabinoid system, found primarily on immune cells. When activated, they can modulate inflammation and immune responses. This study shows they may also influence HIV replication in brain cells.

Read the original research

Differential Effects of Cannabinoid Receptor 2 Agonists on HIV Replication and Inflammatory Activation in Monocyte-Derived Macrophages and Induced Pluripotent Stem Cell-Derived Microglia.

Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology, 20(1), 87

View on PubMed ↗Publisher’s paper ↗

Citation

Starr, Alexander; Rathore, Sara; Daniali, Marzieh; Gaskill, Peter J; Akay-Espinoza, Cagla; Jordan-Sciutto, Kelly L. (2025). Differential Effects of Cannabinoid Receptor 2 Agonists on HIV Replication and Inflammatory Activation in Monocyte-Derived Macrophages and Induced Pluripotent Stem Cell-Derived Microglia.. Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology, 20(1), 87. https://doi.org/10.1007/s11481-025-10254-x